GlassScriptPhysician profile
Bruce H Grossinger
NPI 1578546024
$9,741.70
in general payments reported to CMS, 2019-2025
34 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $951 · 2021: $3,512 · 2022: $2,541 · 2023: $587 · 2024: $648 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,128.75 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $1,385.44 | 2022 | |
| Arteriocyte Medical Systems, INC. | $1,041.78 | 2019-2022 | |
| Allergan, INC. | $965.71 | 2020-2021 | |
| Pfizer INC. | $726.03 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $558.23 | 2019-2024 | Ajovy, Austedo Xr |
| Impel Pharmaceuticals INC. | $316.98 | 2022 | |
| Lilly USA, LLC | $289.85 | 2019-2024 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $274.35 | 2020-2021 | |
| Lundbeck LLC | $190.87 | 2024-2025 | Vyepti |
| Eisai INC. | $165.15 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $164.87 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $124.63 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $122.93 | 2021-2023 | Keveyis |
| Amgen INC. | $122.30 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $118.09 | 2019-2025 | |
| Vertical Pharmaceuticals, LLC | $117.55 | 2019 | |
| Biogen, INC. | $109.18 | 2020-2025 | Spinraza |
| Supernus Pharmaceuticals, INC. | $107.99 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $99.32 | 2020-2021 | |
| Impel Pharmaceuticals LLC | $87.06 | 2024-2025 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $79.61 | 2020-2022 | |
| Ibsa Pharma INC. | $70.95 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $64.88 | 2020-2021 | |
| Si-Bone, INC. | $55.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $53.12 | 2023 | Belsomra |
| Amneal Pharmaceuticals LLC | $48.73 | 2022-2023 | Lyvispah |
| Electronic Waveform Lab, INC. | $30.61 | 2021 | |
| Axsome Therapeutics, INC. | $24.49 | 2025 | Symbravo |
| Vertex Pharmaceuticals Incorporated | $23.39 | 2025 | |
| Nevro Corp. | $23.32 | 2019 | |
| Strongbridge US INC. | $23.05 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.07 | 2023 | Nuedexta |
| Horizon Therapeutics Plc | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Grossinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.